Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bristol Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
February 14, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
February 12, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
RYZB
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
February 07, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC
February 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
February 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
TSVT
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
February 02, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
January 30, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
January 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
January 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
January 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
January 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
January 20, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
January 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
EXEL
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
January 17, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
January 02, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
RYZB
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
December 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
December 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
December 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
December 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
TSVT
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
December 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
December 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
December 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
December 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.